Korro Bio Inc
NASDAQ:KRRO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.3
90
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KRRO stock under the Base Case scenario is 17.87 USD. Compared to the current market price of 52.31 USD, Korro Bio Inc is Overvalued by 66%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Korro Bio Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for KRRO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Korro Bio Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Korro Bio Inc
Balance Sheet Decomposition
Korro Bio Inc
Current Assets | 152.8m |
Cash & Short-Term Investments | 137m |
Receivables | 10m |
Other Current Assets | 5.8m |
Non-Current Assets | 90.8m |
Long-Term Investments | 32.1m |
PP&E | 53.1m |
Other Non-Current Assets | 5.5m |
Current Liabilities | 13.6m |
Accounts Payable | 6m |
Accrued Liabilities | 4.9m |
Other Current Liabilities | 2.8m |
Non-Current Liabilities | 50.3m |
Other Non-Current Liabilities | 50.3m |
Earnings Waterfall
Korro Bio Inc
Revenue
|
0
USD
|
Operating Expenses
|
-108.4m
USD
|
Operating Income
|
-108.4m
USD
|
Other Expenses
|
6.8m
USD
|
Net Income
|
-101.6m
USD
|
Free Cash Flow Analysis
Korro Bio Inc
USD | |
Free Cash Flow | USD |
KRRO Profitability Score
Profitability Due Diligence
Korro Bio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Korro Bio Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
KRRO Solvency Score
Solvency Due Diligence
Korro Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Korro Bio Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KRRO Price Targets Summary
Korro Bio Inc
According to Wall Street analysts, the average 1-year price target for KRRO is 136.51 USD with a low forecast of 106.05 USD and a high forecast of 189 USD.
Dividends
Current shareholder yield for KRRO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
KRRO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).
Contact
IPO
Employees
Officers
The intrinsic value of one KRRO stock under the Base Case scenario is 17.87 USD.
Compared to the current market price of 52.31 USD, Korro Bio Inc is Overvalued by 66%.